Loading cancer entity…
Loading cancer entity…
Clinical trials
806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04152928 | Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities | unknown | N/A | 50 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04154241 | Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor | unknown | N/A | 50 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04140409 |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation(SCIROCCO) |
| terminated |
| Phase 4 |
| 10 |
| Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER |
| 0 |
| Oct 25, 2019 |
| clinicaltrials |
| NCT04134832 | Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region | unknown | — | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01456078 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors(ILUMINET) | completed | Phase 2 | 60 | Lund University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04066322 | Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment(RMPanNET) | unknown | — | 180 | Fudan UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT03053999 | Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) | unknown | — | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT03014297 | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | terminated | Phase 1 | 17 | Lowell Anthony, MDOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04041882 | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02882503 | Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors | withdrawn | N/A | 0 | National Taiwan University HospitalOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02092714 | Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors | unknown | — | 90 | Fox Chase Cancer CenterOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03167853 | Study of JS001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 40 | Peking UniversityOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03982264 | Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm | unknown | N/A | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT02075606 | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients(CALM-NET) | completed | Phase 4 | 50 | IpsenINDUSTRY | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01280201 | Pazopanib as Single Agent in Advanced NETs | completed | Phase 2 | 44 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | unknown | Phase 2 | 112 | Henan Cancer HospitalOTHER_GOV | 0 | May 24, 2019 | clinicaltrials |
| NCT03083210 | Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET | unknown | Phase 4 | 28 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT03948841 | Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences(NETMRI) | completed | — | 41 | CHU de ReimsOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT03930368 | Application of Raw Corn Starch on Patients With Insulinoma | unknown | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01590199 | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(MACS2002) | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00605566 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT00688623 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe(RAMSETE/CDE16) | completed | Phase 2 | 73 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03815838 | Molecular Imaging of Pituitary Adenomas(MIMOPA) | unknown | N/A | 20 | Cardiff UniversityOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03812939 | Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | unknown | — | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01840449 | Somatuline Predictive Factors in Acromegaly and NET(SOPRANo) | completed | — | 156 | IpsenINDUSTRY | 3 | Jan 14, 2019 | clinicaltrials |
| NCT00747786 | Non Interventional Post Marketing Programme in Neuroendocrine Tumours | completed | — | 40 | IpsenINDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT02788578 | A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours(PRELUDE) | terminated | — | 40 | IpsenINDUSTRY | 5 | Dec 21, 2018 | clinicaltrials |
| NCT03017690 | Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | completed | — | 22 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03220087 | Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain(RECOSY) | completed | — | 142 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03749681 | Neuroendocrine Tumors of Old Patients in the West of France(TANGO) | unknown | — | 306 | University Hospital, BrestOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT03717454 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | unknown | N/A | 50 | Zhebao WuOTHER | 0 | Nov 20, 2018 | clinicaltrials |
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | completed | Phase 1 | 81 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 13, 2018 | clinicaltrials |
| NCT00037869 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | completed | Phase 3 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT03723499 | Endoscopic Treatment of Bronchial Carcinoid Tumors | completed | — | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT03714763 | Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA) | unknown | N/A | 50 | Zhebao WuOTHER | 0 | Oct 22, 2018 | clinicaltrials |
| NCT01469572 | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 6, 2019source: clinicaltrials